Chemed Corporation
NYSE:CHEMedical - Care Facilities
+$4.91 today
- Market cap
- $7.12B
- Beta
- 0.54
- P/E (TTM)
- 23.2
- EPS (TTM)
- $19.00
- Dividend yield
- 0.54%
Volume 0.17M
Average 0.25M
CHE Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Chemed CorporationNYSE: CHE
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization grows in line with its trailing trend
Q2 FY2026 depreciation & amortization of $16.99M rose 4.5% year over year, in line with the +4.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at +3.1% a year.
Context
- Depreciation & amortization amounted to 2.6% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +4.5% holds above the trailing-twelve-month pace of +4.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 64.84M USD
- Year-over-year change
- +2.8%
- 4-year CAGR
- +2.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 64.84M | +2.8% |
| FY2024 | 2024-12-31 | 63.05M | +3.6% |
| FY2023 | 2023-12-31 | 60.87M | +2.9% |
| FY2022 | 2022-12-31 | 59.17M | +0.2% |
| FY2021 | 2021-12-31 | 59.05M | — |
Depreciation & Amortization vs competitors
How CHE compares with its peers on the latest reported figures
- CHE's LTM Jun 2026 depreciation & amortization of $66.42M is the 2nd largest of the 5 companies compared; the peer median is $23.4M.
- Its year-over-year change of +4.1% is the lowest of 5, against a peer median of +11.5%.
- Depreciation & amortization amounts to 2.6% of revenue for CHE, versus a peer median of 1.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $73.19M | +7.9% | +2.6% | 1.3% | |
| LTM Jun 2026 | $66.42M | +4.1% | +3.1% | 2.6% | |
| LTM Oct 2026 | $30.08M | +6.5% | -10.1% | 1.1% | |
| LTM Jun 2026 | $16.71M | +15.1% | +5.3% | 1.1% | |
| LTM Mar 2026 | $12.91M | +93.3% | +20.3% | 1.3% | |
| Peer median (excluding CHE) | $23.4M | +11.5% | +4.0% | 1.2% | |
Competitors are the stored peer set for CHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 268.55M | 249.62M | 272.51M | 302M | 265.24M |
| Depreciation & Amortization | 59.05M | 59.17M | 60.87M | 63.05M | 64.84M |
| Deferred Income Tax | (15.78M) | (3.35M) | (8.03M) | (4.14M) | (5.94M) |
| Stock-Based Compensation | 22.5M | 26.25M | 30.08M | 32.03M | 4.89M |
| Change in Working Capital | (26.8M) | (33.49M) | (39.31M) | 8.13M | 23.71M |
| Accounts Receivables | (8.43M) | (2.41M) | (41.49M) | 10.68M | (11.6M) |
| Inventory | (3.01M) | (162K) | (1.73M) | 3.83M | 650K |
| Accounts Payables | 9.83M | 15.34M | (9.35M) | (9.28M) | (5.19M) |
| Other Working Capital | (25.19M) | (46.26M) | 13.26M | 2.9M | 39.85M |
| Other Non-Cash Items | 1.07M | 11.67M | 14.18M | 16.42M | 35.54M |
| Operating Cash Flow | 308.6M | 309.89M | 330.3M | 417.5M | 388.27M |
| Capital Expenditures | (58.68M) | (57.33M) | (56.85M) | (49.53M) | (62.8M) |
| Acquisitions (Net) | 0 | (3.53M) | (3.99M) | (97.4M) | (225K) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 918K | 1.45M | 206K | 3.02M | 3.68M |
| Investing Cash Flow | (57.76M) | (59.4M) | (60.64M) | (143.91M) | (59.34M) |
| Debt Repayment | 196.88M | (99.38M) | (81.75M) | (15.75M) | 10.97M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 27.15M |
| Common Stock Repurchased | (576.04M) | (114.52M) | (67.7M) | (361.39M) | (431.5M) |
| Dividends Paid | (22.02M) | (22.02M) | (23.5M) | (27.09M) | (31.7M) |
| Other Financing Activities | 20.55M | 26.66M | 93.13M | 45.04M | (7.69M) |
| Financing Cash Flow | (380.62M) | (209.25M) | (79.83M) | (359.19M) | (432.77M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (129.78M) | 41.23M | 189.83M | (85.61M) | (103.84M) |
| Free Cash Flow | 249.92M | 252.56M | 273.45M | 367.97M | 325.48M |
Chemed Corporation
NYSE:CHE
Intrinsic Alpha fair value
Locked
Current Price
$546.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.